INSM Quote, Financials, Valuation and Earnings

Cytokinetics has a net margin of -236.04% compared to Insmed's net margin of -34674.95%. Insmed's return on equity of -- beat Cytokinetics's return on equity of --.

Insmed has a consensus price target of $88.25, signalling upside risk potential of 26.78%. On the other hand Cytokinetics has an analysts' consensus of $81.71 which suggests that it could grow by 72.52%. Given that Cytokinetics has higher upside potential than Insmed, analysts believe Cytokinetics is more attractive than Insmed.

Insmed has a beta of 1.103, which suggesting that the stock is 10.328% more volatile than S&P 500. In comparison Cytokinetics has a beta of 0.796, suggesting its less volatile than the S&P 500 by 20.368%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $93.4M, which are larger than Cytokinetics quarterly revenues of $463K. Insmed's net income of -$220.5M is lower than Cytokinetics's net income of -$160.5M. Notably, Insmed's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 31.55x versus 1,574.06x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of -236.04% compared to Insmed's net margin of -4.76%. Insmed's return on equity of -- beat Amicus Therapeutics's return on equity of -71.17%.

Insmed has a consensus price target of $88.25, signalling upside risk potential of 26.78%. On the other hand Amicus Therapeutics has an analysts' consensus of -- which suggests that it could grow by 79.99%. Given that Amicus Therapeutics has higher upside potential than Insmed, analysts believe Amicus Therapeutics is more attractive than Insmed.

Insmed has a beta of 1.103, which suggesting that the stock is 10.328% more volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.599, suggesting its less volatile than the S&P 500 by 40.114%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $93.4M, which are smaller than Amicus Therapeutics quarterly revenues of $141.5M. Insmed's net income of -$220.5M is lower than Amicus Therapeutics's net income of -$6.7M. Notably, Insmed's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 31.55x versus 5.91x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech has a net margin of -236.04% compared to Insmed's net margin of 32.42%. Insmed's return on equity of -- beat Krystal Biotech's return on equity of 6.45%.

Insmed has a consensus price target of $88.25, signalling upside risk potential of 26.78%. On the other hand Krystal Biotech has an analysts' consensus of $207.78 which suggests that it could grow by 30.44%. Given that Krystal Biotech has higher upside potential than Insmed, analysts believe Krystal Biotech is more attractive than Insmed.

Insmed has a beta of 1.103, which suggesting that the stock is 10.328% more volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.799, suggesting its less volatile than the S&P 500 by 20.116%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $93.4M, which are larger than Krystal Biotech quarterly revenues of $83.8M. Insmed's net income of -$220.5M is lower than Krystal Biotech's net income of $27.2M. Notably, Insmed's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 89.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 31.55x versus 19.40x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -236.04% compared to Insmed's net margin of -1141.73%. Insmed's return on equity of -- beat Ocugen's return on equity of -136.91%.

Insmed has a consensus price target of $88.25, signalling upside risk potential of 26.78%. On the other hand Ocugen has an analysts' consensus of -- which suggests that it could grow by 639.12%. Given that Ocugen has higher upside potential than Insmed, analysts believe Ocugen is more attractive than Insmed.

Insmed has a beta of 1.103, which suggesting that the stock is 10.328% more volatile than S&P 500. In comparison Ocugen has a beta of 3.823, suggesting its more volatile than the S&P 500 by 282.261%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $93.4M, which are larger than Ocugen quarterly revenues of $1.1M. Insmed's net income of -$220.5M is lower than Ocugen's net income of -$13M. Notably, Insmed's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 31.55x versus 47.20x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.